Cargando…

External validation of two prediction tools for patients at risk for recurrent Clostridioides difficile infection

BACKGROUND: One in four patients with primary Clostridioides difficile infection (CDI) develops recurrent CDI (rCDI). With every recurrence, the chance of a subsequent CDI episode increases. Early identification of patients at risk for rCDI might help doctors to guide treatment. The aim of this stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Rossen, Tessel M., van Dijk, Laura J., Heymans, Martijn W., Dekkers, Olaf M., Vandenbroucke-Grauls, Christina M. J. E., van Beurden, Yvette H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797589/ https://www.ncbi.nlm.nih.gov/pubmed/33456500 http://dx.doi.org/10.1177/1756284820977385

Ejemplares similares

Simultaneous detection and ribotyping of Clostridioides difficile, and toxin gene detection directly on fecal samples
por: van Rossen, Tessel M., et al.
Publicado: (2021)

Faecal microbiota transplantation for Clostridioides difficile infection: Four years’ experience of the Netherlands Donor Feces Bank
por: Terveer, Elisabeth M, et al.
Publicado: (2020)

An Outbreak of Clostridium difficile Ribotype 027 Associated with Length of Stay in the Intensive Care Unit and Use of Selective Decontamination of the Digestive Tract: A Case Control Study
por: van Beurden, Yvette H., et al.
Publicado: (2016)

Diagnostic yield of repeat sampling with immunoassay, real-time PCR, and toxigenic culture for the detection of toxigenic Clostridium difficile in an epidemic and a non-epidemic setting
por: van Prehn, J., et al.
Publicado: (2015)

Ten-Year Follow-Up of Patients Treated with Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection from a Randomized Controlled Trial and Review of the Literature
por: Ooijevaar, R. E., et al.
Publicado: (2021)

Gut metabolites predict Clostridioides difficile recurrence
por: Dawkins, Jennifer J., et al.
Publicado: (2022)

Epidemiology of community-acquired and recurrent Clostridioides difficile infection
por: Fu, Yichun, et al.
Publicado: (2021)

400. Rehospitalization of Patients for Recurrent Clostridioides difficile Infection
por: Drwiega, Emily, et al.
Publicado: (2022)

2’-Fucosyllactose inhibits proliferation of Clostridioides difficile ATCC 43599 in the CDi-screen, an in vitro model simulating Clostridioides difficile infection
por: Wiese, Maria, et al.
Publicado: (2022)

Risk Factors Associated with Recurrent Clostridioides difficile Infection
por: Negrut, Nicoleta, et al.
Publicado: (2020)

2409. External Validation and Comparison of Clostridioides difficile Severity Scoring Systems
por: Perry, Donald A, et al.
Publicado: (2019)

Using a dog’s superior olfactory sensitivity to identify Clostridium difficile in stools and patients: proof of principle study
por: Bomers, Marije K, et al.
Publicado: (2012)

Esophageal microbiota composition and outcome of esophageal cancer treatment: a systematic review
por: Plat, Victor D, et al.
Publicado: (2021)

Pet Ownership Protects Against Recurrence of Clostridioides difficile Infection
por: Redding, Laurel E, et al.
Publicado: (2020)

Biofilms harbour Clostridioides difficile, serving as a reservoir for recurrent infection
por: Normington, Charmaine, et al.
Publicado: (2021)

Recurrent Clostridioides difficile infection worsens anxiety-related patient-reported quality of life
por: Hengel, Richard L., et al.
Publicado: (2022)

Health-related quality of life in patients with recurrent Clostridioides difficile infections
por: Hammeken, Lianna H., et al.
Publicado: (2022)

Diagnostic Methods of Clostridioides difficile Infection and Clostridioides difficile Ribotypes in Studied Sample
por: Novakova, Elena, et al.
Publicado: (2021)

Virulence Factors of Clostridioides (Clostridium) difficile Linked to Recurrent Infections
por: Tijerina-Rodríguez, Laura, et al.
Publicado: (2019)

Fecal microbiota transplantation for recurrent Clostridioides difficile, safety, and pitfalls
por: Sandhu, Avnish, et al.
Publicado: (2021)

Review of the Impact of Biofilm Formation on Recurrent Clostridioides difficile Infection
por: Rubio-Mendoza, Daira, et al.
Publicado: (2023)

Pseudomembranes on colostomy in a patient with recurrent Clostridioides difficile infection
por: Ueda, Hideki, et al.
Publicado: (2023)

Iron Regulation in Clostridioides difficile
por: Berges, Mareike, et al.
Publicado: (2018)

Fidaxomicin to prevent recurrent Clostridioides difficile: what will it cost in the USA and Canada?
por: Patel, Devangi, et al.
Publicado: (2023)

Investigational Treatment Agents for Recurrent Clostridioides difficile Infection (rCDI)
por: Kullar, Ravina, et al.
Publicado: (2020)

Patient Perception of Route of Rectal Administration of Live Biotherapeutic Product for Recurrent Clostridioides difficile Infection
por: Feuerstadt, Paul, et al.
Publicado: (2023)

External validation of clinical prediction rules for complications and mortality following Clostridioides difficile infection
por: Beauregard-Paultre, Catherine, et al.
Publicado: (2019)

Microbiota in Clostridioides difficile-Associated Diarrhea: Comparison in Recurrent and Non-Recurrent Infections
por: Gazzola, Alessandra, et al.
Publicado: (2020)

2565. Initial and Recurrent Episodes of Clostridioides difficile: Online Education as a Tool to Improve Management Strategies
por: Hurst, Simi Thomas, et al.
Publicado: (2019)

Analysis of the impact of secondary prophylaxis on Clostridioides difficile recurrence in critically ill adults
por: Connor, Kathryn A, et al.
Publicado: (2020)

390. Eravacycline combination therapy for severe, recurrent, or fulminant Clostridioides difficile infection
por: Morrison, Austin R, et al.
Publicado: (2022)

789. Evaluation of Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection in Patients at High Risk for Recurrence
por: Johnson, Tanner M, et al.
Publicado: (2020)

Effectiveness of Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection Among Transplant Recipients
por: Johnson, Tanner M, et al.
Publicado: (2021)

Battling Enteropathogenic Clostridia: Phage Therapy for Clostridioides difficile and Clostridium perfringens
por: Venhorst, Jennifer, et al.
Publicado: (2022)

2382. Recurrent Clostridioides difficile Infection (CDI) Worsens Anxiety-Related Patient-Reported Quality of Life
por: Garey, Kevin W, et al.
Publicado: (2019)

Plasmid-mediated metronidazole resistance in Clostridioides difficile
por: Boekhoud, Ilse M., et al.
Publicado: (2020)

Identification of the Unwinding Region in the Clostridioides difficile Chromosomal Origin of Replication
por: Oliveira Paiva, Ana M., et al.
Publicado: (2020)

Incidence and Risk Factors of Recurrent Clostridioides difficile Infection in Patients With Cirrhosis
por: Phatharacharukul, Parkpoom, et al.
Publicado: (2020)

Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Clostridioides difficile Infection
por: Escudero-Sánchez, Rosa, et al.
Publicado: (2020)

Immunological mechanisms of fecal microbiota transplantation in recurrent Clostridioides difficile infection
por: Soveral, Lucas F, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e188v923miqiisrjb3n2h18q58